Acquisition Context Polyplus Transfection acquired Xpress Biologics at the end of 2022, creating a potential channel for cross-selling additional services and leveraging Polyplus’ broader Advanced Therapeutics portfolio to offer GMP-grade material production and scale-up capabilities.

Small Scale Expert Operate at 100 mg to 10 g scale with microbial expression systems (E. coli and P. pastoris) and GLP/R&D quality, enabling rapid prototyping and early preclinical materials that can feed into larger GMP manufacturing pipelines.

One-Stop Solutions Position as a single point of contact for screening, development, and transfer to CMOs, offering coordination of subcontractors for antibody development, plasmid DNA, and recombinant proteins to expedite preclinical programs.

IP Free Advantage Processes are IP-free and designed for regulatory and scale-up readiness, providing a clear value proposition for customers seeking easier transfer to GMP-grade production and smoother regulatory pathways.

Targeted Markets Focus on preclinical therapeutic and diagnostic markets requiring plasmid DNA and recombinant protein production, with potential upsell into GMP-grade manufacturing and clinical study support through existing Polyplus Transfection relationships.